MARKET

SANA

SANA

Sana Biotechnology, Inc.
NASDAQ
2.770
-0.260
-8.58%
After Hours: 2.820 +0.05 +1.81% 19:19 03/27 EDT
OPEN
3.010
PREV CLOSE
3.030
HIGH
3.066
LOW
2.770
VOLUME
2.59M
TURNOVER
--
52 WEEK HIGH
6.55
52 WEEK LOW
1.260
MARKET CAP
739.22M
P/E (TTM)
-2.8728
1D
5D
1M
3M
1Y
5Y
1D
Sana Biotechnology files Form 3; EVP and Chief Scientific Officer Dhavalkumar Dhirajlal Patel reports 99,510 common shares owned directly
Reuters · 1d ago
Weekly Report: what happened at SANA last week (0316-0320)?
Weekly Report · 6d ago
Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal
NASDAQ · 03/20 14:13
Weekly Report: what happened at SANA last week (0309-0313)?
Weekly Report · 03/16 09:20
Durable HIP Technology Data De‑Risks Sana Biotechnology’s SC451 Program and Supports Buy Rating
TipRanks · 03/13 16:45
Sana Biotechnology Gains on Positive Results for Type 1 Diabetes Study
Dow Jones · 03/13 16:22
Sana Biotechnology Reports Continued Positive 14-Month Results In Type 1 Diabetes Cell-Therapy Study
NASDAQ · 03/13 14:52
BUZZ-Sana Biotechnology rises as cell transplant shows promise in type 1 diabetes treatment
Reuters · 03/13 13:15
More
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

Webull offers Sana Biotechnology Inc stock information, including NASDAQ: SANA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SANA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SANA stock methods without spending real money on the virtual paper trading platform.